AVEO Oncology announces completion of CHMP oral explanation for Tivozanib
AVEO Oncology announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, as part of the Marketing Authorization Application, review process for tivozanib as a treatment for patients with first-line renal cell carcinoma. It is expected that with the oral explanation complete, the CHMP will proceed to an opinion which they will submit to the European Commission, which has the authority to approve medicines for use in the 28 countries in the European Union. The opinion is expected to be announced at a future CHMP meeting. Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor. It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib has been investigated in several tumors types, including renal cell, colorectal and breast cancers.